Interstitial cystitis & bladder pain syndrome

What is interstitial cystitis / bladder pain syndrome?

The American Urological Association defines IC/BPS as an unpleasant sensation (pain, pressure, or discomfort) perceived to be related to the urinary bladder, together with lower urinary tract symptoms such as urgency or frequency, lasting more than six weeks, in the absence of infection or another identifiable cause. Three parts of that definition do real work. The pain is *perceived in* the bladder, which is not the same as being *caused by* the bladder. It is persistent rather than a passing episode. Everything else, infection above all, has been ruled out.

The name has changed over the decades. 'Interstitial cystitis' literally means inflammation within the bladder wall, but most people with the diagnosis turn out to have no visible inflammation at all. That is why clinicians and researchers now prefer bladder pain syndrome, or the combined label IC/BPS. The defining feature is the pain experience rather than any proven bladder pathology.

It is far more common than its reputation suggests. The RAND Interstitial Cystitis Epidemiology (RICE) studies, the first rigorous population-based estimates in the United States, found that 2.7% to 6.5% of adult women meet symptom criteria. That works out to roughly 3.3 to 7.9 million U.S. women, most of them never formally diagnosed. A companion study in men found 1.9% to 4.2% meeting criteria, overlapping heavily with what gets labeled chronic prostatitis. IC/BPS is neither rare nor exclusively a women's condition.

What does IC/BPS feel like?

The core symptoms cluster around the bladder and its filling cycle:

• Pain, pressure, or burning felt in the bladder, urethra, lower abdomen, or pelvis. It classically builds as the bladder fills and eases, at least briefly, after emptying.
• Urgency: a persistent, uncomfortable need to urinate, driven by pain or pressure rather than fear of leaking.
• Frequency that often runs far beyond the normal range, including waking repeatedly at night.
• Pain with sex (dyspareunia), common in both women and men.
• Flares, meaning days or weeks when everything intensifies, often after certain foods or drinks, stress, sitting for long periods, sexual activity, or hormonal shifts.

Two patterns are worth noticing. First, symptoms characteristically wax and wane, alternating flares with quiet stretches, rather than marching steadily downhill. Second, many people hurt in more places than the bladder: pelvic floor muscles that are tender and tight, and for a substantial subgroup, pain elsewhere in the body entirely. That second pattern turns out to be one of the most important clues to what is actually going on, as the MAPP findings below show.

What are Hunner lesions, and why does the distinction matter?

Look inside the bladders of people diagnosed with IC/BPS and you find two very different pictures. They differ enough that many researchers now argue these are two different conditions sharing one label.

A 2019 review by Whitmore and colleagues put it directly: Hunner-lesion IC is a distinct inflammatory disease of the bladder, while non-Hunner IC/BPS shows little evidence of bladder pathology and instead behaves like a disorder of nervous-system sensitization, frequently accompanied by body-wide symptoms.

This is why the distinction matters practically: the 2022 AUA guideline update emphasizes checking for Hunner lesions with cystoscopy when the diagnosis or treatment plan would change, because lesion-directed treatment helps that subgroup specifically. If you have the far more common non-Hunner form, repeated bladder-directed procedures are less likely to be the answer, and approaches aimed at the pain system itself move toward the center of the plan.

What does the nervous system have to do with bladder pain?

For over a decade, the NIH-funded MAPP Research Network (Multidisciplinary Approach to the Study of Chronic Pelvic Pain) has studied people with IC/BPS and related pelvic pain using brain imaging, sensory testing, and long-term symptom tracking. Its findings reframed the condition:

• The pain often isn't confined to the pelvis. MAPP identified two broad phenotypes: people whose pain stays pelvic, and people with widespread pain across the body. The widespread group carries higher rates of overlapping conditions such as fibromyalgia, irritable bowel syndrome, chronic fatigue, and migraine.
• Sensitivity is measurably elevated far from the bladder. In quantitative sensory testing, people with urologic chronic pelvic pain were more sensitive to pressure at the *thumbnail* than healthy controls, and greater sensitivity tracked with worse clinical pain. That is a signature of central sensitization: amplification in the spinal cord and brain rather than trouble in the organ.
• Brain structure and function differ. MAPP neuroimaging studies found altered brain networks in patients, particularly in the widespread-pain phenotype.
• The phenotype predicts what helps. A 2025 MAPP re-analysis of clinical trials found that patients with mostly localized pain tended to respond to bladder-directed therapy, while patients with widespread pain responded to treatments aimed at the pain system itself. That is evidence for matching treatment to mechanism rather than to organ alone.

None of this makes the pain less real. Sensitization is a physical process in real neural circuits, as measurable as inflammation. What it changes is the target. If you recognize yourself in the overlap pattern of bladder pain plus gut symptoms, body-wide tenderness, fatigue, and migraine, our neuroplastic pain quiz can help you gauge whether central sensitization may be part of your picture to raise with your clinician.

When is it not IC? Red flags that need prompt evaluation

IC/BPS is a diagnosis of exclusion, which means some symptoms should never be filed under it without a proper workup. See a clinician promptly if you notice any of the following:

• Visible blood in the urine. Gross hematuria is never part of IC/BPS and always needs evaluation to rule out stones, infection, or a tumor.
• Fever, chills, or feeling systemically ill with urinary symptoms. That points to an active infection of the bladder, kidneys, or prostate, which needs treatment rather than IC self-care.
• Inability to empty the bladder, or leaking with a bladder that won't empty. Retention (with or without overflow incontinence) is a different problem with its own urgent causes.
• Blood in the urine plus a history of smoking. Smoking is the leading risk factor for bladder cancer, and this combination warrants a urology referral even if the bleeding is painless and even if it stops.
• New pelvic pain with unexplained weight loss, or neurological changes such as numbness in the saddle area or new leg weakness. These need evaluation for causes outside the bladder.

None of these mean the worst-case explanation is likely. They mean the diagnosis of IC/BPS should only ever be made after they have been checked. A good workup is what makes the reassurance underneath this diagnosis trustworthy.

How is interstitial cystitis diagnosed?

There is no blood test, scan, or biomarker that proves IC/BPS. Diagnosis, per the AUA guideline, is built from a careful history and targeted exclusion:

1. History and symptom mapping: the character and location of the pain, its relationship to bladder filling and emptying, urinary frequency and urgency, flare triggers, and how long it has all lasted (more than six weeks).
2. Urinalysis and urine culture to exclude infection. This step matters doubly, because many people with IC/BPS have spent months or years being treated for 'recurrent UTIs' that never grew bacteria.
3. A physical exam including the pelvic floor. Tender, tight pelvic floor muscles are found in a large share of patients and change the treatment plan.
4. Further tests only when indicated, such as post-void residual measurement, urine cytology if there are cancer risk factors, and cystoscopy when Hunner lesions are suspected or the picture is atypical. Urodynamics and bladder biopsy are not routine.

Two practical notes. First, ask whether your evaluation looked for Hunner lesions, since finding them opens specific treatments. Second, a diagnosis of IC/BPS is not a dead end or a brush-off. It is the starting point of a well-mapped treatment ladder, and it usually explains years of confusing test results.

How is IC/BPS treated?

The AUA's 2022 guideline reorganized treatment away from a rigid first-line-to-sixth-line sequence into categories chosen through shared decision-making, starting with the lowest-risk options and escalating only as needed, often combining several at once:

• Education and self-care. Understanding the condition, including the role of the nervous system, is itself treatment. Add stress management, sleep care, gentle activity, and identifying personal flare triggers. For many people those triggers are certain foods and drinks, and an individualized elimination-and-reintroduction approach beats blanket restriction.
• Pelvic floor physical therapy. For patients with pelvic floor tenderness, specialized manual physical therapy is one of the best-supported treatments in the field: in a randomized multicenter trial, 59% of women responded to myofascial physical therapy versus 26% with generic massage. Note this is *release-oriented* therapy. Strengthening exercises like Kegels can make an already-guarded pelvic floor worse.
• Oral medications. Several classes are used, each with modest average benefit and real trade-offs. One long-used IC drug carries a recognized risk of eye damage with long-term use, which the guideline now specifically flags for counseling. Which medication, if any, fits your situation is a decision to make with your clinician, not from a webpage.
• Bladder instillations and procedures. These include medication delivered directly into the bladder, cystoscopy with hydrodistension, and, for the Hunner subgroup specifically, lesion-directed treatment that can bring marked relief. Neuromodulation and other interventions sit further up the ladder.
• Major surgery. Reserved for rare, severe, treatment-refractory cases, almost always involving Hunner-type disease. The guideline treats it as a true last resort.

The principle is to match the treatment to your phenotype. Hunner lesions call for lesion-directed care, a tender pelvic floor calls for physical therapy, and widespread pain with overlapping conditions calls for treating the sensitized pain system, which the next section covers. For the broader landscape of options, see our guide to chronic pain treatment.

Where do brain-and-nervous-system approaches fit?

If the MAPP research shows that much of non-Hunner IC/BPS runs on central sensitization, then treatments that retrain the pain system belong alongside urologic care rather than in place of it. In practice that means:

• Pain neuroscience education, meaning learning how a protective brain can amplify signals from a healthy organ. For many people this alone reduces the fear that feeds the flare cycle.
• Stress- and threat-reduction practices. The bladder is densely wired into the stress response, which is why flares track life load.
• Graded re-engagement: steadily reclaiming the activities, foods, travel, and intimacy that fear of flares has taken, rather than letting the map of 'safe' living shrink. Our guide to living with chronic pain covers the day-to-day toolkit.
• Treating the overlap rather than the organ alone. When IC/BPS travels with fibromyalgia, IBS, or chronic pelvic pain, a nervous-system-directed approach can address the shared mechanism underneath all of them at once.

This mirrors the MAPP finding that widespread-pain patients respond best to centrally-acting treatment. Structured brain-retraining programs, including Karuna's VR-based program for chronic pain, apply these principles to the sensitized pain system generally. Whether that fits your specific situation is a conversation for your clinician, and it complements rather than replaces urologic evaluation and care.

When should you see a doctor?

Sooner than most people with bladder pain do. Reasonable thresholds:

• Bladder or pelvic pain lasting more than six weeks. That is the definitional threshold for IC/BPS, and the point at which 'wait and see' stops being a plan.
• Any red flag from the list above, promptly: visible blood, fever with urinary symptoms, retention, or hematuria with a smoking history.
• 'Recurrent UTIs' where the cultures keep coming back negative. This pattern is one of the most common roads to a delayed IC/BPS diagnosis, and it deserves a fresh look rather than another antibiotic course.
• Symptoms that are eroding sleep, work, intimacy, or mood. That is the threshold for asking about the full treatment ladder, including pelvic floor physical therapy and, where the picture fits, nervous-system-directed care.

A urologist or urogynecologist can anchor the workup. A pelvic floor physical therapist and a clinician versed in chronic pain often round out the team. Bring a symptom diary. Flare timing, triggers, and the relationship of pain to bladder filling tell a diagnostic story that a single office visit cannot.